Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial
2025.12.27
ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices
2025.12.27
Professor Zhang Yonghong: Two Decades of Transformation in Precision Diagnosis and Treatment of Pediatric Lymphoma in China
2025.12.27
58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer
2025.12.27
ASH 2025 | Prof. Jeff Sharman on Mosunetuzumab and Treatment Advances Beyond R-CHOP
2025.12.26
ASH 2025 | Live Insights on Next-Generation Immunotherapies
2025.12.26
ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation 
2025.12.25
ASH China Voice | Professor Du Juan: First-Line BCMA/CD19 Dual-Target FasTCAR-T Redefines Outcomes for Patients with Newly Diagnosed Multiple Myeloma
2025.12.25
ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma
2025.12.25
Professor Zhisong He: Advances and Unresolved Challenges in the Treatment of Non–Muscle-Invasive Bladder Cancer
2025.12.25
Posted inHematology Frontier

Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial

Posted by By Mourabit Halima 2025.12.27
Continue Reading
Posted inHematology Frontier

ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices

Posted by By Mourabit Halima 2025.12.27
Continue Reading
ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

Posted by By Mourabit Halima 2025.12.17
On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…
Read More
ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

Posted by By Peng Longmei 2025.12.17
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…
Read More
ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

Posted by By Mourabit Halima 2025.12.17
At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…
Read More
ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

Posted by By Peter W. PENG 2025.12.16
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…
Read More
ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

Posted by By Peng Longmei 2025.12.16
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…
Read More
ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

Posted by By Mourabit Halima 2025.12.16
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…
Read More
ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

Posted by By Mourabit Halima 2025.12.15
To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…
Read More
TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

Posted by By Mourabit Halima 2025.12.15
At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…
Read More
Professor Yige Bao: Perioperative Vidicitamab Plus Immunotherapy Enables Kidney-Sparing Treatment in High-Risk UTUC

Professor Yige Bao: Perioperative Vidicitamab Plus Immunotherapy Enables Kidney-Sparing Treatment in High-Risk UTUC

Posted by By Peng Longmei 2025.12.14
Editor’s note: Upper tract urothelial carcinoma (UTUC) accounts for about 17.9% of all urothelial carcinomas (UC) in China. For high-risk UTUC, radical nephroureterectomy (RNU) is the standard surgical procedure, but…
Read More
NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?

NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?

Posted by By Mourabit Halima 2025.12.14
Editor’s note: The incidence of genitourinary cancers in China has continued to rise, with prostate, bladder, and kidney cancers ranking among the most common malignancies. Among them, eosinophilic renal tumors…
Read More

Posts pagination

Previous page 1 … 4 5 6 7 8 … 20 Next page
Recent Posts
  • Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial
  • ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices
  • Professor Zhang Yonghong: Two Decades of Transformation in Precision Diagnosis and Treatment of Pediatric Lymphoma in China
  • 58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer
  • ASH 2025 | Prof. Jeff Sharman on Mosunetuzumab and Treatment Advances Beyond R-CHOP
Recent Comments
    Archives
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inHematology Frontier
    Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial
    Posted by By Mourabit Halima 2025.12.27
    Posted inHematology Frontier
    ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices
    Posted by By Mourabit Halima 2025.12.27
    Posted inHematology Frontier
    Professor Zhang Yonghong: Two Decades of Transformation in Precision Diagnosis and Treatment of Pediatric Lymphoma in China
    Posted by By Peng Longmei 2025.12.27
    Posted inIOncology
    58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer
    Posted by By Mourabit Halima 2025.12.27
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied